Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* Male or female subjects of any race, ages 18-75 inclusive~* Meets the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM 5) criteria for Bipolar I or Bipolar II Disorder or MDD~* The start of the current major depressive episode is at least 2 weeks but no more than 6 months prior to the Screening (Visit 1)~* Has at least moderate severity of illness, as measured by a rater-administered MADRS total score ≥ 24 and corresponding to a CGI S score of ≥ 4 at Screening (Visit 1) and Baseline (Visit 2)~* The patient meets the DSM-5 criteria for mixed-features specific to the Bipolar I or II diagnosis or MDD diagnosis~* Current major depressive episode is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning~* Able to provide written informed consent~Major Exclusion Criteria:~* Any female subject who is pregnant or breast-feeding~* Any subject judged to be medically inappropriate for study participation~* The patient has a significant risk for suicidal behavior~* The patient presents with a lifetime history of epilepsy, seizure or convulsion, or electroencephalogram with clinically significant abnormalities, delirium, dementia, amnestic, or other cognitive disorder or significant brain trauma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lumateperone 42mg (Type: EXPERIMENTAL): Lumateperone 42mg administered once daily in the evening
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo administered once daily in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).